



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 941 072 B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
14.01.2004 Bulletin 2004/03

(21) Application number: 97912341.1

(22) Date of filing: 13.11.1997.

(51) Int Cl.⁷: **A61K 9/28**

(86) International application number:
PCT/GB1997/003121

(87) International publication number:
WO 1998/020861 (22.05.1998 Gazette 1998/20)

(54) **METHOD AND APPARATUS FOR THE COATING OF SUBSTRATES FOR PHARMACEUTICAL USE**

VERFAHREN UND GERÄT ZUR BESCHICHTUNG VON SUBSTRATEN ZUR
PHARMAZEUTISCHEN VERWENDUNG

PROCEDE ET DISPOSITIF SERVANT A REVETIR DES SUBSTRATS A USAGE
PHARMACEUTIQUE

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority: 13.11.1996 GB 9623634

(43) Date of publication of application:
15.09.1999 Bulletin 1999/37

(73) Proprietor: **Phoqus Pharmaceuticals Limited**
Goudhurst, Kent TN17 1HR (GB)

(72) Inventors:
• **BROWN, Steven, Robert**
Sittingbourne, Kent ME10 2TE (GB)

• **REEVES, Linda, Ann**
Chislehurst, Kent BR7 5JQ (GB)
• **STANIFORTH, John, Nicholas**
Bath BA2 2AT (GB)

(74) Representative: **Bardo, Julian Eason et al**
Abel & Imray
20 Red Lion Street
London WC1R 4PQ (GB)

(56) References cited:
EP-A- 0 277 741 WO-A-92/14451
WO-A-96/35413 GB-A- 1 561 100

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

BEST AVAILABLE COPY

EP 0 941 072 B1

Description

[0001] The present invention relates to methods of coating substrates, to apparatus for coating substrates and to coated substrates for pharmaceutical use. In particular, but not exclusively, the invention relates to the coating of pharmaceutical substrates to produce solid dosage forms.

[0002] It is to be understood that the term "solid dosage form" is to be interpreted in a broad sense as covering a wide variety of pharmaceutical products. Thus the term covers pharmaceutical products to be taken orally, for example, pharmaceutical tablets of conventional shape as well as capsules and spherules and tablets of unconventional shape. It will be understood that the pharmaceutical substrate may be a conventional tablet core or may be for example an edible sheet or film. The term also covers pharmaceutical products not taken orally, for example, a pessary, a bougie, a suppository or a patch for application to the skin. Also, where reference is made to "pharmaceutical substrate" it is to be understood that the term covers the substrates of the solid dosage forms indicated above. The term "solid dosage form" does not, however, include pharmaceutical products such as small pellets and granules, for example small pellets which are filled into capsule shells for administration and granules which are compressed to form tablets. Such pellets or granules are not themselves each solid dosage forms but rather, when combined together in a capsule or tablet, define in combination a solid dosage form.

[0003] The invention is of particular application to pharmaceutical tablets of conventional shape. Where reference is made throughout the specification to pharmaceutical tablets, it should be understood that this should be interpreted in a broad sense, unless it is clear to the contrary, as covering also other pharmaceutical products taken orally, for example capsules and spherules.

[0004] It will be understood that the term "active material" and "active component" used throughout the specification includes material which is biologically active and will comprise one or a mixture of pharmaceutical materials. The pharmaceutical materials include those materials which are administered for the prevention and/or treatment of disease.

[0005] In a conventional method of producing a pharmaceutical tablet, a mixture containing the biologically active ingredient together with diluents such as lactose and other ingredients is mixed and portions of the mixture are formed into discrete tablets by, for example, pressing samples of the mixture.

[0006] The resulting tablet core may be coated using, for example, a conventional liquid coating technique in which the tablet cores are tumbled in a drum while liquid coating material is sprayed onto the surfaces of the tablet cores. The liquid coating on the surfaces of the cores is usually dried by heating to dry the coating.

[0007] A problem with the method of producing tablets described above is that, due to inhomogeneity of the mixture from which the tablet cores are made, the amount of active ingredient in the resulting tablet cores varies from one tablet to the next. While that is a problem for all types of tablet core produced in that way, it is a particularly serious problem when the amount of active ingredient in each core is low, for example for active compounds of high activity. In that case a small absolute variation in the percentage amount of active ingredient in the cores corresponds to a significant variation in the dose contained in each tablet which is clearly most undesirable.

[0008] Various solutions to that problem have been proposed.

[0009] In one method, the active ingredient and a small amount of diluent are granulated together and the granulated mixture is added to further diluent. The mixture is then compressed in the usual way to form tablet cores. Using that method, at each stage the proportion of active ingredient added to the diluent is high thus helping to reduce the variation in the dose in each tablet core. However, the variation in the dose for tablets formed by this method is still found to be as much as $\pm 15\%$.

[0010] In an alternative known method, a two-layer tablet core is produced by compressing a powder having a lower layer of diluent and an upper layer of diluent mixed with the active ingredient. Cores formed by this method, however, require special designs of presses and are found to have a relatively large variation in their contained dose. They also require reformulation of the components making up the core. Also, such presses generally have lower rates of production of cores than standard presses.

[0011] In another known method, a coating solution containing active material is applied to the surfaces of small beads using conventional spray coating techniques, for example by spraying the coating solution towards the beads as they are tumbled in a revolving drum. The coated beads are filled into capsule shells for administration. Such a method is not appropriate for use where accuracy in the amount of the active material applied to the cores is required because there is little control over the amount of coating material applied to each core using that method.

[0012] It is an object of the invention to overcome or mitigate one or more of the above mentioned disadvantages.

[0013] EP 0 277 741 relates to a method of producing spherical coated granules, generally 14-80 mesh in size, for filling into capsules. The granules are coated with a drug and a low substituted hydroxypropylcellulose, and a further coating is optionally applied in a fluidized bed. The specification describes spraying the active powder together with hydroxypropylcellulose (binder) solution, and spraying again with hydroxypropylcellulose powder, followed by drying at 40°C under reduced pressure and then enteric coating.

[0014] GB 1 561 100 relates to a special solid pharmaceutical dosage form produced by coating a web with a material containing a medicament, and then fabricating the web into a solid geometric form so as to substantially internalize the medicament, for example by lamination or winding, and unitizing the geometric form to produce a plurality of unit dosage forms which are then sealed so the medicament is completely internalized.

5 [0015] EP 0 259 749 relates to a special drug dosage form comprising a film-like carrier material coated with a coating containing active agent which is subdivided into removable oral dosage units. There can be different coating layers, and a protective layer may be applied over the active agent-containing layer. A smooth roll coating process is described. The active agent may be applied to the carrier material in the form of an aqueous solution and then dried or applied as a pre-formed film.

10 [0016] LU 52460 relates to a local anaesthetic material comprising a sheet comprising a water-soluble film-forming material and a local anaesthetic. The sheet may be formed from a solution of the film-forming material and the anaesthetic by spray coating or by spreading or casting the solution on a surface and heating the solution, and the dried film can be converted to pieces of the desired size and shape. The sheet material may be covered with a water insoluble backing and a removable sheet to protect against contamination.

15 [0017] None of these discloses electrostatic overcoating on top of an active material layer.

[0018] WO 92/14451 describes methods of electrostatically coating conventional tablet cores containing active ingredient with a powder coating material, but only non-active coating material and application of a single coating layer are described.

20 [0019] According to the invention, there is provided a method of coating a pharmaceutical substrate, the method comprising the steps of:

(a) applying an active coating material to a surface of the substrate to form an active coating layer, the active coating material comprising biologically active material and

25 (b) electrostatically applying a cover coating material onto the active coating layer to form a cover coating layer such that the active coating layer is substantially completely covered by the cover coating layer.

[0020] Thus biologically active material is applied to the outer surface of the substrate. In the case of pharmaceutical tablets, active material is applied to an outer surface of a preformed pharmaceutical tablet core. The active coating material may therefore be applied to the substrate in a small quantity and thus the percentage of biologically active component in the active coating material mixture may be high, leading to less variation in the amount of active material from one dosage form to the next compared with the known methods described above.

30 [0021] The active coating material may be applied to a substrate which contains no biologically active material or may be applied to a substrate which contains the same or a different biologically active material. Thus the method may be used to provide a solid dosage form which contains one active component in the substrate and a different active component as a coating on the surface of the substrate. It is envisaged that those active components could be released at different rates.

[0022] The active material may be applied to a substrate to which one or more coating layers have already been applied. For example, where the substrate is a tablet core containing active material, the core may be coated with a delayed release coating prior to the application of the active coating material.

40 [0023] Where the material containing active components is applied to the outer surfaces of a pharmaceutical substrate as a coating, the layer containing the active components will be susceptible to damage resulting in loss of active material. By applying a cover coating over the surface of the active coating layer the active coating layer is protected from damage. That protection is especially desirable when the coating material contains a small amount of active component. In addition to protection from physical damage, the coating may also provide protection from chemical damage; for example, the cover coating may be moisture resistant and/or may give delayed release of the active components.

45 [0024] It is clearly preferable for the cover coating to cover completely all of the active coating but incomplete coating, for example at the edge of the active coating layer, may be tolerated in some circumstances.

[0025] While the cover coating will often comprise a single coating of one material composition, it may comprise more than one coating and/or coatings including more than one composition.

50 [0026] Where there is more than one cover coating, a preformed sheet or film may be applied as one of the coatings.

[0027] Preferably, the active coating material is applied electrostatically. There are various advantages in applying coating materials electrostatically, for example, reduction in waste of coating material, improved coating efficiency and improved coating weight uniformity.

55 [0028] In one embodiment of the invention, the active coating material is applied in the form of a dry powder.

[0029] Advantageously, at least 90% by weight of the particles of the active coating material have a particle size not more than 200 μm .

[0030] Advantageously, at least 90% by weight of the particles of the active coating material have a particle size

between from 1 to 200 μm . Preferably, at least 90% by weight of the particles of the active coating material have a particle size between from 1 μm to 100 μm . The term "particle size" refers to the equivalent particle diameter of the particles and may be measured using, for example, laser light diffraction. The particle size of the powder is an important factor in powder coating techniques. If the particles of the powder are very small, the powder will often be too cohesive for successful powder application using many powder coating techniques. However, large particles can be disadvantageous because they are often more difficult to coat onto a surface and, if the coating material is to be fused after application to the surface, longer fusing times may be required, leading to increased risk of damage to the substrate and to the active component.

[0031] Where reference is made to % by weight of particles, for example the % by weight of particles having a particular size, the particles will also preferably have that % by volume of particles of that size.

[0032] Alternatively, the coating material may be applied in the form of a liquid.

[0033] Advantageously, the method includes the step of applying a metered dose of the active coating material to a surface of the substrate.

[0034] In conventional coating methods, the part to be coated, for example, a pharmaceutical tablet core, is tumbled in a revolving drum while coating material is sprayed into the drum such that coating material is applied to all of the surfaces of the cores. It has been proposed that the substrate may be supported on a surface while coating material is sprayed towards exposed surfaces of the substrate. A problem with such methods is that there is a large variation in the amount of coating material applied to each core. While that can be tolerated where the coating is, for example, a cosmetic coat, where the coating material contains active material, very accurate application of the coating material on each surface is required.

[0035] Advantageously, a metered dose of coating material is applied to each substrate, thus allowing for the application of the required amount of active material to each substrate. This is to be contrasted with the known methods where coating material is sprayed towards the cores. In that case the amount of coating material applied to each substrate depends on many factors all of which would require close control if accurate application is to be achieved. It will be understood that whilst reference is made to applying a metered dose, that should not be taken to imply that there is necessarily any measurement of the amount of material applied.

[0036] The active coating material may be applied in the form of a jet of particles of coating material

[0037] Advantageously, the active coating material is applied in the form of a liquid. Thus a metered volume of liquid may be applied to each substrate.

[0038] Advantageously, the active coating material is applied in the form of individual liquid droplets which are propelled from the supply directly towards a surface of the substrate.

[0039] Where the material is applied as a plurality of individual droplets, it is more simple to alter the dose of active material applied to the substrate by changing the number of droplets applied. Thus advantageously, the number of droplets applied is controllable.

[0040] Advantageously, substantially all of the active coating material released from the supply is applied to a surface of a substrate. It is highly preferable for there to be little or no overspray of the coating material.

[0041] Advantageously, a predetermined number of droplets of active coating material are applied to the surface of the substrate. Thus where the droplets are of the same size, the number of droplets applied to the substrate surface determines the amount of active material applied. By altering the number of droplets applied, the apparatus used can easily be adapted to apply the required quantity of active material.

[0042] Advantageously, the coating material is applied in the form of a jet of liquid droplets directed at an exposed surface of the substrate. Whereas known spray devices for use in coating processes spray a wide area with coating material, a jet of liquid droplets allows material to be applied more accurately with less overspray.

[0043] Advantageously, the method is such that the coefficient of variation of the quantity of active coating material applied to each substrate (or region of the substrate) is not more than 15%.

[0044] As indicated above, where the coating material includes active material, the accuracy and reproducibility of the application of the material to the substrates is of particular importance. For known spraying techniques such as those described above, the coefficient of variation can be 50% or more. Whilst that is acceptable where the coating is a cosmetic coating, it is not acceptable where the coating contains active material. Preferably the coefficient of variation is not more than 10%, and most preferably 3% or less.

[0045] Advantageously, an ink jet head is used to apply coating material to the substrate. A conventional ink jet head, for example those used for ink jet printers, can be used to apply an easily controllable amount of material from the head onto a substrate.

[0046] Advantageously the active coating material is applied to only a part of the surface of the substrate.

[0047] Advantageously, the area of the surface of the substrate covered by the active coating layer is less than 40% of the total surface area of the substrate. Advantageously, the area covered by the active coating layer is less than 25% of the total surface area of the substrate. The active coating may form a plurality of small coated regions on the surface of the substrate.

[0048] Advantageously, the active coating layer covers only a part of the exposed surface of the substrate. The area of the exposed surface covered by the active coating layer may be less than 10% of the total area of the exposed surface.

[0049] Where the quantity of active material to be administered using each solid dose is small, as indicated above, it is advantageous for the proportion of active component in the active coating material to be large.

[0050] In conventional coating methods the part to be coated, for example a pharmaceutical tablet core, is tumbled in a revolving drum during the coating process such that coating material is applied to all of the surfaces of the core.

[0051] By using the method described above, a smaller proportion of the surface of the substrate is covered and therefore a smaller amount of coating material may be used. Thus the proportion of active component in the coating material is increased.

[0052] Another problem with the known methods described above is that there is overspray of coating material which has to be discarded or recycled. That would be particularly disadvantageous in a method according to the present invention in which the coating material contains an active component.

[0053] Using the method described above, coating material may be applied accurately to a predetermined part of the substrate, thereby helping to reduce loss of powder due to overspray.

[0054] Advantageously, the area of the surface covered by the active coating layer is less than 25%, preferably less than 10% of the total area of the surface. Preferably, the coated area is less than 5% of the total area. The active coating material may be applied to the surface of the substrate in the form of a small spot.

[0055] Advantageously, the cover coating is applied to only a part of the surface of the substrate. Thus, as described below, where the substrate is a pharmaceutical tablet core, the cover coating material may be applied to one face only of the tablet core.

[0056] The cover coating may cover only a part of the exposed surface of the substrate.

[0057] Advantageously, the active coating material further includes one or more excipients. The formulation will usually consist of the active component and a mixture of excipients that will aid in the coating of the material. The formulation may also include other components, for example, colorants and/or flavourings and/or agents to control the rate of release of the active component.

[0058] Advantageously, the substrate is supported on a support means during the coating of the active coating material. This is particularly advantageous where the substrate is fragile, for example a tablet core, because the likelihood of damage to the substrate is reduced. Supporting of the substrate also allows the application of the coating material to be more accurate and the uniformity of coating can be improved compared with the case in which the substrate is, for example, tumbled in a revolving drum during the coating stage, as is conventional practice for the coating of tablet cores.

[0059] Advantageously, the support means conveys the substrate through a region adjacent to a source of the active coating material. That allows the method to be continuous.

[0060] In one advantageous embodiment of the invention, the method comprises supporting the substrate adjacent to the source of the active coating material with a surface of the substrate maintained at such a different electric potential from that of the active coating material that the application of the electric potential causes the active coating material to move from the source of the active coating material towards the substrate, a surface of the substrate becoming coated with the active coating material.

[0061] Preferably, the substrate is supported from above and the powder moves from the source upwards towards a lower surface of the substrate.

[0062] Preferably, the substrate is charged when the substrate is adjacent the source of the active coating material. Alternatively, or in addition, the source of active coating material may be charged.

[0063] The method may further include the step that after the active coating layer is applied the active coating material is treated to form an active film coating secured to the surface of the substrate. Where the coating material is in the form of a powder material, the treatment advantageously comprises a heating step, preferably by infra red radiation, but other forms of electromagnetic radiation may be used. Usually, the change in the coating upon heating will simply be a physical change from a powder to a liquid and then, on cooling, to a solid coating, but there are other possibilities: for example, the powder coating may comprise a polymer which is cured during the treatment step, for example by irradiation with energy in the gamma, ultra violet or radio frequency bands, to form a cross-linked polymer coating.

[0064] Alternatively, the active coating material applied to the surface of the substrate might not be treated to form an active film coating. The cover coating applied subsequently over the active coating material could be used to seal the active coating on the surface of the substrate.

[0065] Where the coating material is in the form of a liquid, the treatment advantageously comprises drying the coating material with a heater although other methods could be used.

[0066] The coating material containing the active component is susceptible to damage at high temperatures and it is therefore particularly important that the temperature of treatment is not high. Advantageously, the temperature of treatment is less than 250°C, preferably less than 200°C and more preferably less than 150°C. Where the higher treatment temperatures are used, the duration of the treatment is advantageously short to reduce the possibility of

damage of the coating material.

[0067] The cover coating material is applied electrostatically. The cover coating material may be in the form of a powder. The cover coating material may also include active material. The active material in the cover coating may be the same or different from the active material in the active coating layer.

5 [0068] Advantageously, at least 90% by weight of the particles of the cover coating material have a particle size not more than 200 μm , preferably between from 1 to 200 μm .

[0069] Advantageously, the substrate is supported on a support means during the coating of the cover coating material. As indicated above, that reduces the risk of damage of the substrate and can increase the accuracy of the application of the coating.

10 [0070] Preferably, the support means conveys the substrate through a region adjacent to a source of the cover coating material.

[0071] In one advantageous embodiment of the invention, the method comprises supporting the substrate adjacent to the source of the cover coating material with a surface of the substrate maintained at such a different electric potential from that of the cover coating material that the application of the electric potential causes the cover coating material to move from the source of the cover coating material towards the substrate, a surface of the substrate becoming coated with the cover coating material.

15 [0072] Advantageously, the substrate is supported from above and the powder moves from the source upwards towards a lower surface of the substrate.

[0073] Preferably, the substrate is charged when the substrate is adjacent to the source of the cover coating material..

20 Alternatively, or in addition, the source of cover coating material may be charged.

[0074] Advantageously, the method further includes the step that after the cover coating layer is applied the cover coating material is treated to form a film coating secured to the surface of the substrate. The treatment of the cover coating layer may be similar to that of the active coating layer described above.

25 [0075] As indicated above, in a preferred embodiment of the invention the active coating layer covers only part of a surface of the substrate. In that embodiment, the cover coating layer may cover only part of a surface of the substrate. The cover coating layer may cover the whole surface of the substrate.

[0076] The method may further include the step of applying a further coating material to a surface of the substrate to form a further coating layer. The further coating material may include biologically active material, the further coating layer forming a further active coating layer and the method may further include the step of applying a further cover coating material onto the further active coating layer to form a further cover coating layer such that the further active coating layer is substantially completely covered by the further cover coating layer.

30 [0077] Thus substrates having two or more different active components may be produced. The cover coating material covering the first active coating may be different from that covering the second active coating so that the rate of release of the first active component may be different from that of the second active component. Alternatively, the two active components may be the same and the cover coatings may be the same or different materials. One or more of the cover coating materials may contain active material.

35 [0078] Advantageously, the method is continuous. In practice, there are considerable advantages in being able to operate the coating process continuously rather than as a batch process.

[0079] Advantageously, the coated pharmaceutical substrate is a solid dosage form, preferably a solid dosage form for oral administration.

40 [0080] Where reference is made to the quantity of active coating material being substantially equal to a dose of the active material, it will be understood that the quantity of one dose may be a fraction of the single standard dose, for example $1/2$ or $1/3$ of a single standard dose of the active material. It will be understood that the quantity of active material will depend on the active component used and the number of solid dosage forms to be taken by the patient for each dose. Where more than one layer of the active coating material is to be applied to each substrate, the quantity of active component in each layer will be chosen accordingly.

[0081] For example, where the active material is applied to the surface of a conventional tablet core, the amount of active material applied to each core will usually contain one dose of the active component.

50 [0082] Where the substrate is other than a conventional tablet core, for example where the substrate is in the form of a film or sheet, a plurality of regions of active coating material may be applied to the surface of the substrate.

[0083] The amount of active coating material applied to each region may be chosen so as to contain substantially one dose of the active component. In that embodiment, the method advantageously further includes the step of dividing the coated substrate to form a plurality of solid dosage forms. In the example described above, each solid dosage form would include substantially one dose of the active material. The cover coating may be applied before the coated substrate is divided. Alternatively, the cover coating may be applied after the dividing step.

55 [0084] The invention also provides a method of coating a substrate, the method comprising applying an active coating material to a surface of the substrate to form an active coating layer, the active coating material comprising biologically active material, electrostatically applying a cover coating layer over the exposed surfaces of the active coating layer

and dividing the layered product to form layered portions, each layered portion including substantially one dose of the active material.

[0085] A particularly preferred embodiment of the invention provides a method of coating a substrate, the method comprising applying an active powder material to a surface of the substrate to form an active coating layer, the active coating material comprising biologically active material and being applied electrostatically to the surface of the substrate, and applying a cover coating over the exposed surfaces of the active coating layer to substantially completely cover the active coating layer on the surface of the substrate, the cover coating also being applied electrostatically.

[0086] It will be appreciated that once the cover coating layer has been applied over the exposed surfaces of the active coating layer, a further coating layer may be applied such that the final product is substantially completely coated.

[0087] For example, where the substrate is a pharmaceutical tablet core, the active coating layer and cover coating layer may be applied to one face of the tablet core. The partially coated core may subsequently have a further coating applied to the uncoated surfaces of the core.

[0088] Advantageously, the substrate is moved relative to a source of active coating material during the application of the active coating layer to the substrate.

[0089] The invention also provides apparatus for coating a pharmaceutical substrate according to a method as described above which comprises:

- (a) a source of active coating material, the active coating material comprising biologically active material,
- (b) support means for supporting a substrate adjacent to the source of the active coating material,
- (c) means for applying the active coating material to a surface of the substrate, such that the active coating material forms an active coating layer on the surface,
- (d) a source of a cover coating material,
- (e) means for conveying the substrate having the active coating layer to a position adjacent to the source of cover coating material, and
- (f) means for electrostatically applying the cover coating material onto the active coating layer such that the cover coating material forms a cover coating layer which substantially completely covers the active coating layer.

[0090] The apparatus advantageously includes means for applying both the active coating material and the cover coating material electrostatically. As indicated above, the coating material may be applied in the form of a dry powder or in the form of a liquid.

[0091] Advantageously, the source of active coating material comprises a conveyor for conveying active coating material through a region in which the substrate is supported by the support means.

[0092] The conveyor may comprise a conveyor belt. Where the conveyor is used it is possible to provide a substantially uniform supply of coating material to the region in which the coating is applied.

[0093] Advantageously the apparatus further includes means for supplying active coating material to the source, comprising a reservoir of active coating material arranged adjacent to the conveyor, and means for transferring the active coating material from the reservoir to the conveyor. The rate of transfer of the coating material from the reservoir to the conveyor can be adjusted to change the amount of coating material applied to the substrate.

[0094] Advantageously, the means for transferring the active coating material includes charging means for applying a charge to the conveyor. The charge may be applied using a corona charge wire adjacent to the conveyor. The charged conveyor attracts coating material from the reservoir onto the surface of the conveyor from where it is conveyed to the region in which the coating is applied. Thus it is possible to obtain a very thin uniform layer of coating material on the conveyor surface.

[0095] Preferably, the reservoir is arranged below the conveyor.

[0096] Advantageously, the source comprises means for applying a metered dose of active coating material on a surface of the substrate. The source may comprise an ink jet head.

[0097] The source may comprise means for directing droplets of liquid active coating material towards a surface of the substrate.

[0098] The apparatus may comprise means for applying active coating material from the source onto only a part of the surface of the substrate.

[0099] The means for applying the coating material may include means for directing coating material towards the surface of the substrate in the form of a jet of liquid droplets. The means for forming a jet of liquid droplets may be similar to devices known in the field of ink jet printing heads for directing liquid droplets of ink towards a printing surface.

[0100] The apparatus may further include means for applying a cover coating material onto only a part of the surface of the substrate.

[0101] According to the invention, there is also provided a pharmaceutical product comprising a substrate, a fused-film active coating layer on a surface of the substrate, the active coating layer comprising biologically active material, and a fused-film cover coating layer that has been applied electrostatically on the active coating layer, substantially

completely covering the active coating layer.

[0102] The pharmaceutical product may further include a second active coating layer, and a cover coating layer substantially completely covering the second active coating layer. In the case of a tablet, for example, the first active coating layer may cover one face of the tablet and the second active coating layer may cover the opposite face of the tablet.

[0103] The cover coating layer covering the first active coating layer may be different from the cover coating layer covering the second active coating layer. Thus different release rates of the two active coatings may be obtained as described above.

[0104] Advantageously, the coated pharmaceutical product is a solid dosage form, preferably a solid dosage form to be administered orally.

[0105] The substrate may contain biologically active material. As indicated above, the method according to the invention is particularly suitable for the case in which the quantity of active component to be administered is low. Where a large quantity of a first active component is to be co-administered with a small quantity of a second active component, the first active component may be present in the substrate, for example the tablet core, in the usual way and the second active component may be contained in a coating on the surface of the substrate in accordance with the present invention.

[0106] The active coating layer may cover only a part of the surface area of the substrate. The active coating may cover less than 25% of the surface area of the substrate. Where the substrate is a tablet core, the active coating layer covers less than the total area of a face of the core.

[0107] Preferably the area covered by the active coating material layer is less than 20%, more preferably less than 10%. In one preferred embodiment of the invention, the coating material layer is in the form of a spot of material on the surface of the substrate.

[0108] The coating layer may be shaped, for example to form a pattern, a picture, symbols, letters or numerals.

[0109] The cover coating layer may cover only a part of the surface of the substrate.

[0110] The invention also provides a pharmaceutical product made by a method described above.

[0111] A further aspect of the invention provides a method of coating a pharmaceutical substrate, the method including the step of applying an active coating material to a surface of the substrate to form a coating layer, the active coating material comprising biological material, in which the active coating layer covers only a part of the surface of the substrate.

[0112] It will be understood that the method according to the further aspect of the invention could include a combination of the features described above and may include features of the method described above.

[0113] Embodiments of the invention will now be described by way of example having reference to the drawings of which:

Figure 1 shows schematically a side view of an apparatus for coating a tablet core in accordance with the invention;

Figure 2 shows schematically a side view of a part of the apparatus of Figure 1;

Figure 3 shows schematically a cross sectional view of part of the apparatus of Figure 1; and

Figures 4a to 4c show cross sectional views of tablet cores coated in accordance with the invention.

[0114] The apparatus shown in Figure 1 is for coating both faces of pharmaceutical tablet cores. The apparatus comprises an inclined tablet core feed chute 1 leading to a first rotatable wheel 2 having circular depressions 3 in its outer surface. The cores 4 are fed from the chute 1 into the depressions 3 where they are held by suction by means of a suction line 5 in communication with the base of the depression 3 via an opening. The first drum is rotated in the direction shown by the arrow A. Adjacent to the outer surface of the wheel 2 downstream from the feed chute 1 is an active coating station 6 and a cover coating station 7. Downstream from the active coating station is an active coating fusing station 8 at which the active coating is fused and downstream from the cover coating station 7 is a cover coating fusing station 9 at which the cover coating is fused. A cooling station (not shown) may be provided downstream from each of the fusing stations 8, 9 where cool air is directed at the core to cool the fused coating.

[0115] A second wheel 10 similar to the first wheel 2 is arranged adjacent to the first wheel 2, the nip between the wheels being downstream of the fusing station 9. The second wheel 10 rotates in an opposite sense to that of the first wheel 2 as shown by the arrow B. Arranged adjacent to the outer edge of the second wheel 10 downstream from the nip of the two wheels are a second cover coating station 11 and a second fusing station 12.

[0116] The tablet cores are fed continuously from the core feed chute 1 to the depressions 3 in the rotating wheel 2. The core lies over the opening in the depression 3 leading to the suction line 5 and the core is held in the depression by suction. The core is moved on the rotating wheel 2 to the active coating station 6 where active coating including biologically active material is applied as described in more detail below and is fused at the active coating fusing station 8. The core then moves to the cover coating station 7 where a further coating is applied over the active coating. The

coated core then moves to the fusing station 9 where a heater fuses the cover coating to form a film coating secured to the core.

[0117] When the core in the depression 3 reaches the nip between the two wheels, the suction holding the core in the depression 3 is released and the core is transferred into a depression 3' on the surface of the rotating second wheel 10 where it is held by suction with coated surfaces of the core adjacent to the surfaces of the depression and the uncoated surfaces of the tablet exposed.

[0118] The second wheel 10 moves the core to the second cover coating station 11 and the second fusing station 12 and a second cooling station (not shown) to form a fully coated tablet core.

[0119] The core is then moved to an exit chute 1'. The suction holding the core is released and the core drops from the wheel along the chute which takes the cores to be further processed and/or packed.

[0120] It will be understood that where only one face of the tablet core is to be coated, the second wheel 10 would be omitted. Further, where an active coating of material including biologically active material is to be coated onto both faces of the tablet, a further active coating station 6' would be positioned by the second wheel upstream from the second cover coating station.

[0121] It will be appreciated that the coating material in each of the two cover coating stations may be the same or different materials, and where more than one active coating station is used, the coating material in each of the active coating stations may be the same or different materials.

[0122] Figure 2 shows the active coating device 6 in more detail. Figure 2 shows a portion of the wheel 2 together with a core 4 in a depression 3 on the surface of the wheel 2.

[0123] The active coating station 6 comprises a conveyor 13 arranged in a loop in a vertical plane so that the upper surface 14 faces the surface of the wheel and the cores 4 which pass the device 6 as the wheel rotates. The contour of the upper surface 14 of the conveyor 13 is chosen to match the contour of the outer surface of the wheel so that the distance between the core and the upper surface of the conveyor is unchanged as the wheel rotates. The direction of rotation C of the conveyor 13 is such that the direction of movement of the upper surface of the conveyor is opposite to that of the movement of the core over the upper surface of the conveyor. Alternatively, the direction of movement of the upper surface of the conveyor and the core may be the same.

[0124] As shown in Figure 2, a corona charge wire 15 and a powder source 16 are arranged beneath the conveyor immediately below the lower surface 17 of the conveyor.

[0125] The corona charge wire 15 sprays charge onto the lower surface 17 of the conveyor. It will be appreciated that a different method could be used to apply charge to the conveyor.

[0126] The powder source 16 uses an archimedes screw to form a small mound of powder beneath the lower surface of the conveyor. The source 16 comprises a hopper 18 containing the powder including the biologically active component, and an Archimedes screw 19 which in use passes through the powder material 20 in the hopper 18 and through a vertical barrel 21. Thus, the powder material 20 is circulated from the lower regions of the hopper 18 to the top of the barrel 21 where a moving heap of powder is formed. The heap will be of substantially constant size and shape as excess powder overflows from the top of the barrel 21 and is returned to the hopper 18.

[0127] Stirrers 22 are provided in the hopper 18 to help to improve the flow of the powder and break up any agglomerates.

[0128] Thus a small moving heap of powder of substantially constant size and shape is formed beneath the lower surface of the conveyor 17.

[0129] It will be appreciated that a device other than the Archimedes screw could be used to form the heap of powder.

[0130] The powder source 16 is located downstream from the charge spraying device 15 and powder from the heap of powder is attracted to the surface of the charged conveyor 17 where it forms a thin, uniform layer which is transported to the upper surface 14 of the conveyor.

[0131] The tablet core 4 passing over the upper surface of the conveyor is held at a different potential from that of the conveyor 13, either by earthing the core or applying a charge to the core as described below, and powder on the conveyor moves from the conveyor to the exposed surfaces of the tablet core 4 to form a powder coating.

[0132] The active coating station 6 is enclosed in a housing (not shown) to reduce the risk of powder loss of the active powder. In use the housing has an opening above the upper surface of the conveyor 14 so that the tablet core 4 is exposed to the active powder coating material as it passes the station 6.

[0133] It will be appreciated that the thickness of the powder layer formed on the surface of the tablet core depends on several factors including the amount of charge sprayed onto the conveyor, the magnitude of the charge applied to the core, the size of the heap of powder produced, the size of the opening in the housing and the speed of the conveyor. Those factors will be varied to give the desired coating depending on the type of powder and core used.

[0134] The tablet core including the active coating then passes to the active coating fusing station 8 which comprises a heater which is used to fuse the coating material. A cooler situated downstream from the active coating fusing station 8 directs air at the core to cool the fused active coating.

[0135] The active coated tablet core then passes to the cover coating station 7 where a charge is applied to the

tablet core as described below and the core is passed over an earthed trough containing the cover coating powder. The powder from the trough is attracted to the exposed surfaces of the tablet core to form a cover coating over the active coating. The tablet then passes to the cover coating fusing station 9 where the cover coating is fused to form a film coating and to a cooling station where cool air is directed at the core to cool the fused coating.

[0136] As shown in Figure 3, where a charge is to be applied to the tablet core at one or more of the coating stations, each depression 3 is electrically insulated from the other depressions on the wheel by means of a cup of insulating material 23 and is provided with a respective pick up arm 24 extending radially inward from the depression 3 towards but ending short of the centre of the wheel. The pick up arms 24 are attached to the inner surface of the wheel 2 and rotate with it. Each associated pick up arm 24 and depression 3 together make a moving electrode which is in contact with the core 4 when it is located in the depression 3.

[0137] A stationary electrode 25 is located inside the wheel at each angular position corresponding to each coating station, as required. The outer surfaces of the stationary electrodes are at the same radial distance from the centre of the wheel as the free ends of the pick up arms 24 of the moving electrodes. As the wheel 2 rotates, the moving electrodes contact the stationary electrodes and a charge is applied to the tablet core 4 in the depression 3.

[0138] The partially coated tablet core then passes onto the second wheel, and the uncoated surfaces are coated with a cover coating in a similar way.

[0139] Figures 4a and 4b show schematic cross-sectional views of tablets coated in accordance with the first aspect of the present invention. The tablet shown in Figure 4a comprises a core 4, an active coating layer 26 comprising active material covering the upper surface and part of the side surface of the core, and a cover coating 27 covering the active coating layer 26. The core also has a further cover coating 28 covering the opposite face and part of the side surface of the core. The further cover coating 28 may be of the same or different composition as that of the cover coating 27.

[0140] It will be appreciated that the thickness of the coating layers relative to the size of the core have been greatly exaggerated for clarity. For a tablet core of thickness 5mm, the thickness of each coating layer would usually be of the order of from 5 to 100 μm .

[0141] Where the apparatus described above is used to coat the cores, most of the coating material deposited on the core surface will be deposited on the face of the core facing the powder source such that the coating on that face of the core will be thicker than the coating on the exposed side faces of the core where less coating material is deposited.

[0142] Figure 4b shows a tablet having an active coating 26' and a cover coating 27'. The tablet is similar to that of Figure 4a except that there is no further cover coating on the opposite side of the core.

[0143] It will be appreciated that tablets having other combinations of active coatings and cover coatings could be produced. For example, a first coating containing no active material may be applied to all or part of the surfaces of the substrate before the application of the active coating material. For example, where the substrate also includes active material, the first coating may be a delayed release coating.

[0144] The composition of the active coating material used will of course depend on the active ingredient to be used and the amount of the coating to be applied.

[0145] Active materials most suitable to be applied to the tablet include those materials having a high therapeutic activity, for example those where the usual prescribed dose is about 1mg or less, and which have a good stability to degradation due to heat where the coating material containing active material is to be heated.

[0146] An active material which may be applied to a tablet core in accordance with the invention is Diltiazem HCL.

[0147] The amount of active ingredient to be coated onto each core or other substrate will generally be small and the active ingredient will usually be diluted with one or more excipients. The excipients used will be chosen so that they aid the coating of the active material onto the cores by, for example improving the electrostatic properties of the powder and its physical properties and aiding the formation of the fused active coating, for example the excipient may be a material which melts at a low temperature to aid the formation of a film.

[0148] Where the active coating material is a powder, the particle size will be an important factor with regard to the transfer of the active coating material from the conveyor to the tablet core and to the subsequent fusing of the material. Usually a particle size range of 1 to 200 μm will be used (at least 90% of the particles of the powder having a size within that range).

[0149] One example of an active coating material is as follows:

Xylitol	45% wt
Diltiazem HCL (active)	45% wt
TiO ₂	9% wt
Colloidal silica	1% wt

[0150] It is thought that in at least one embodiment of the invention, the active composition will comprise three main components together with additives.

[0151] The components may, for example, comprise the following

- i) a continuous phase component, for example Xylitol or PEG 6000,
- ii) the active component,
- iii) a particle seed and/or charge modifying component, for example TiO_2 or silica,
- iv) a flow aid, for example colloidal silica or magnesium stearate.

[0152] Each component may comprise one or more different materials.

[0153] The active coating material of the above example was in the form of a powder and had a particle size distribution such that at least 90% wt of the particles had a size in the range of from 5 to 25 μm . It is often preferred that at least 90% by weight of the particles have a size in the range of from 1 to 45 μm . In one preferred embodiment 90% by weight of the particles have a size less than 70 μm ; 50% by weight have a particle size less than 40 μm and 10% by weight of the particles have a size less than 10 μm .

[0154] The active powder coating material may be produced using one or a combination of the following processing steps:

- a) precipitation of two or more of the components to form composite particles
- b) spray drying of two or more of the components to form composite particles
- c) granulation
- d) extrusion
- e) micronisation.

[0155] For example, all of the components of the composition may be co-micronised to give a powder material having the desired particle size.

[0156] An example of a powder cover coating material is as follows:

39.75%	Eudragit RS (ammonio-methacrylate copolymer)
39.75%	Klucel (hydroxy propyl cellulose)
15.0%	Titanium dioxide
5.0%	Aluminium lake
0.5%	Aerosil 200 (colloidal silicon dioxide)

[0157] The cover coating material was prepared by the following method:

a) A sample containing the % wt of components listed above was premixed in a high shear mixer. Water was added to the mixture in a high shear mixer for a few minutes to give a granulated mixture which was dried in a fluid bed drier at a temperature of about 45°C for 20 to 30 minutes to give a material having a moisture content (measured as loss on drying) below 3% by weight. The material was impact milled and then micronised using a fluid energy mill to a powder containing particles having a size distribution such that 50% by volume of particles were of a size less than 20 μm .

[0158] The cover coating material will usually include components to control the dissolution rate of the cover coating to give controlled release of the active material in the active coating layer. Where more than one active coating is applied to each tablet or other substrate, the release of each active coating can be different where different materials are used for the cover coating over each of those active coatings.

[0159] Where one or more of the coatings are applied as liquid coatings, a suitable liquid coating device would be used at the active coating station 6 and/or the cover coating station 7 and the fusing device would be replaced by, for example a drying device to dry the liquid coating, if necessary.

[0160] In an alternative embodiment of the invention, an ink jet printer head is used to apply active coating and/or cover coating material in an apparatus similar to that described above and as shown in Figures 1 and 3.

[0161] The head may be an ink jet printer head, for example an adapted Compact 200 head manufactured by Alphadot Limited. That head has 5 outlets spread over an area of about 10mm and can be used to direct liquid coating material towards the exposed surfaces of the tablet core such that, for a tablet core having two parallel flat faces, the liquid coating substantially completely covers one of the flat faces.

[0162] It will be understood that different types of head may be used to apply coating material to the surface of the substrate and that the head will be chosen so as to give the desired deposition of the coating material on the surface of the substrate to be coated. For example, where the coating is to cover only a part of the exposed surface of the

substrate, the size and arrangement of the outlets will be chosen accordingly.

[0163] Where, for example, active coating material is to be applied to a tablet core using an ink jet printer head using the apparatus shown in Figures 1 and 3, the printer head is arranged at the active coating station 6 and active coating material in the form of a liquid is applied to a surface of a pharmaceutical tablet core held on the first wheel 2. A head for applying the liquid is positioned such that the outlet or outlets of the head is less than 1mm from a surface of a tablet core held on the wheel 2 at the active coating station 6.

[0164] The liquid coating material comprises the active component and a solvent, preferably water, and an excipient, for example PEG, to aid in film forming. Preferably the solids content of the liquid coating material is very low, advantageously there would be substantially no solids content and advantageously the active material is fully dissolved in the solvent.

[0165] Examples of active liquid coating materials which may be used are as follows

a)	Sodium citrate	0.02
	Chlorpheniramine maleate	2.48
	Propylene glycol	4.00
	Water	18.50
	Ethanol	75.00

b)	Sodium citrate	0.02
	Chlorpheniramine maleate	2.00
	Methocel E15	1.00
	Lactose B.P.	6.00
	PEG 4000	1.00
	Water	89.98

[0166] The amounts given above represent percentage by weight of each component.

[0167] The apparatus may include heating means 8 downstream from the coating station 6 for drying the applied coating material. However, where the liquid coating material is such that the solvent evaporates quickly, the heater 8 may not be required. It will be appreciated that where the heater 8 is used the temperature required to dry the active coating will be significantly lower than the temperature required to fuse powder coating material as described above.

[0168] The apparatus may further include a cover coating station 7 and a fusing station 9 as described above and, where the core is to be further coated, the apparatus includes a second wheel 10 with a coating station 11 and fusing station 12 as described above. Where a further active coating is to be applied, a further active coating station and, optionally, a further heater may be provided upstream from the coating station 11. An example of a suitable cover coating material is described above.

[0169] Figure 4c shows a tablet coated by a method described above. The tablet comprises a core 4, a first active coating layer 26" covering substantially all of the upper face of the core, a cover coating 27" covering the active coating layer and part of the sides of the tablet core, a second active coating layer 29 covering part of the lower surface of the core and a second cover coating layer 28 covering the second active coating layer 29. The two active coating layers 26" and 29 may include the same or different active ingredients; the two cover coating layers 27" and 28 may be of the same or different material and may have different dissolution rates.

[0170] Where the active coating material is applied using the method described above, substantially all of the coating material is applied to a face of the tablet core, with substantially no coating material being applied to the sides of the tablet core.

[0171] In a further embodiment of the invention, the active coating material is applied to a substrate using an ultrasonic spray head. The ultrasonic spray head forms a cloud of liquid droplets which are charged electrostatically. A charge may be imparted on the droplets, for example, by applying a high voltage to the ultrasonic spray head. The charged droplets become attracted to the substrate which is at a potential difference from the droplets.

[0172] It will be appreciated that the apparatus described above could be modified for the coating of pharmaceutical substrates other than conventional tablet cores. As indicated above, the method and apparatus described could be used to coat tablet cores of non-conventional shape or pharmaceutical substrates in the form of a film or sheet.

Claims

1. A method of coating a pharmaceutical substrate, the method comprising the steps of:

- 5 (a) applying an active coating material to a surface of the substrate to form an active coating layer, the active coating material comprising biologically active material, and
(b) electrostatically applying a cover coating material onto the active coating layer to form a cover coating layer such that the active coating layer is substantially completely covered by the cover coating layer.

10 2. A method as claimed in claim 1, wherein the active coating material is applied electrostatically.

3. A method as claimed in claim 1 or claim 2, wherein the active coating material is applied in the form of a dry powder.

15 4. A method as claimed in claim 3, wherein at least 90% by weight of the particles of the active coating material have a particle size in the range of from 1 μm to 45 μm .

5. A method as claimed in any one of claims 1 to 4, wherein the active coating material is applied in the form of a jet of particles of coating material.

20 6. A method as claimed in any one of claims 1 to 5, wherein the active coating material is applied in the form of a liquid.

7. A method as claimed in claim 6, wherein the active coating material is applied in the form of individual liquid droplets which are propelled from the supply directly towards a surface of the substrate.

25 8. A method as claimed in claim 6 or claim 7, wherein a predetermined number of droplets of active coating material are applied to the surface of the substrate.

9. A method as claimed in any of claims 6 to 8, wherein the active coating material is applied in the form of a jet of liquid droplets directed at an exposed surface of the substrate.

30 10. A method as claimed in any one of claims 1 to 9, wherein an ink jet head is used to apply active coating material to the substrate.

35 11. A method as claimed in any one of claims 1 to 10, wherein the method further includes the step that after the active coating layer is applied the active coating material is treated to form an active film coating secured to the surface of the substrate.

40 12. A method as claimed in claim 11, wherein the active coating material is in the form of a powder and after the active coating layer is applied the active coating material is treated to form a fused film coating secured to the surface of the substrate.

13. A method as claimed in any one of claims 1 to 12, wherein the cover coating material is in the form of a powder.

45 14. A method as claimed in claim 13, wherein after the cover coating layer is applied the cover coating material is treated to form a fused cover film coating secured to the surface of the substrate.

15. A method as claimed in any one of claims 1 to 14, wherein the active coating material is applied to only a part of the surface of the substrate.

50 16. A method as claimed in claim 15, wherein the active coating layer is in the form of a spot or forms a pattern, picture, symbol, letter or numeral.

17. A method as claimed in claim 15 or claim 16, wherein the cover coating material covers only a part of the surface of the substrate.

55 18. A method as claimed in any one of claims 1 to 17, wherein the cover coating layer provides controlled release of the biologically active material.

19. A method as claimed in any one of claims 1 to 18, wherein the cover coating includes biologically active material.
20. A method as claimed in claim 19, wherein the biologically active material in the cover coating is the same as that in the active coating.
21. A method as claimed in claim 19, wherein the biologically active material in the cover coating is different from that in the active coating.
22. A method as claimed in any one of claims 1 to 21, wherein the method further includes the step of applying a further coating material to a surface of the substrate to form a further coating layer.
23. A method as claimed in claim 22, wherein the further coating material includes biologically active material, the further coating layer forming a further active coating layer.
24. A method as claimed in claim 23, wherein the method further includes the step of applying a further cover coating material onto the further active coating layer to form a further cover coating layer such that the further active coating layer is substantially completely covered by the further cover coating layer.
25. A method as claimed in claim 24, wherein the biologically active material in the further active coating layer is different from that in the first active coating layer.
26. A method as claimed in claim 25, wherein the biologically active material in the further active coating layer is the same as that in the first active coating layer, and the cover coating materials are different.
27. A method as claimed in any one of claims 24 to 26, wherein one or more of the cover coating materials contains biologically active material.
28. A method as claimed in any one of claims 1 to 21, wherein the method further includes the steps of applying a further coating material which includes biologically active material to form a second active coating layer, and applying a further cover coating material onto the second active coating layer to form a further cover coating layer such that the second active coating layer is substantially completely covered by the further cover coating layer.
29. A method as claimed in claim 28, wherein the cover coating layer covering the first active coating layer is different from the cover coating layer covering the second active coating layer.
30. A method as claimed in any one of claims 1 to 29, wherein the substrate is in the form of a film or sheet.
31. A method as claimed in any one of claims 1 to 30, wherein the coated pharmaceutical substrate is a solid dosage form.
32. A method as claimed in claim 31, wherein the solid dosage form is for oral administration.
33. A method as claimed in claim 32, wherein the solid dosage form is a tablet or capsule.
34. A method as claimed in any one of claims 1 to 30, wherein the total quantity of biologically active material in the coated substrate is substantially equal to a dose of the active material.
35. A method as claimed in any one of claims 24 to 27, wherein the pharmaceutical substrate is a tablet core and the first active coating layer covers one face and the second active coating layer covers the opposite face.
36. A method as claimed in claim 35, wherein, to provide different release rates, the cover coating layer covering the first active coating layer is different from the cover coating layer covering the second active coating layer.
37. A method as claimed in any one of claims 1 to 30, wherein a plurality of regions of active coating material are applied to the surface of the substrate.
38. A method as claimed in any one of claims 1 to 30 or claim 37, which method includes the step of dividing the coated substrate to form a plurality of solid dosage forms.

39. A method as claimed in claim 38, wherein the cover coating is applied before the coated substrate is divided.

40. A method as claimed in claim 37, wherein the cover coating is applied after the coated substrate is divided.

41. A method as claimed in any one of claims 1 to 30, which comprises the steps of:

- (a) applying a plurality of regions of active coating material to a surface of the substrate, the active coating material comprising biologically active material, the amount of active coating material applied to each region being such as to contain substantially one dose of biologically active material, and
- (b) electrostatically applying cover coating material onto the active coating material such that the active coating material is substantially completely covered by cover coating material,

and dividing the coated substrate before or after application of the cover coating material such that each divided portion contains substantially one dose of biologically active material.

42. A method as claimed in any one of claims 1 to 30, wherein the layered product is divided to form layered portions, each layered portion including substantially one dose of the biologically active material.

43. A method as claimed in any one of claims 1 to 42, wherein the substrate contains the same biologically active material as is applied to the substrate.

44. A method as claimed in any one of claims 1 to 42, wherein the substrate contains different biologically active material from that applied to the substrate.

45. A method as claimed in claim 44, wherein the substrate and the active coating layer have different release rates.

46. A method as claimed in any one of claims 43 to 45, wherein the substrate is a tablet containing biologically active material coated with a delayed release coating prior to application of the active coating material.

47. A method as claimed in any one of claims 1 to 42, wherein the substrate contains no biologically active material.

48. A method as claimed in any one of claims 1 to 47, wherein the substrate is supported on a support means during the coating with the active coating material and/or the cover coating material.

49. A method as claimed in claim 48, wherein the method comprises supporting the substrate adjacent to the source of the active coating material and/or the cover coating material with a surface of the substrate maintained at such a different electric potential from that of the active coating material and/or cover coating material respectively that the application of the electric potential causes the active coating material and/or cover coating material to move from the source of the active coating material and/or cover coating material towards the substrate, a surface of the substrate becoming coated with the active coating material and/or cover coating material.

50. A method as claimed in claim 48 or claim 49, wherein the substrate is supported from above and the powder moves from the source upwards towards a lower surface of the substrate.

51. An apparatus for coating a pharmaceutical substrate, the apparatus comprising:

- (a) a source of active coating material, the active coating material comprising biologically active material,
- (b) support means for supporting a substrate adjacent to the source of the active coating material,
- (c) means for applying the active coating material to a surface of the substrate such that the active coating material forms an active coating layer on the surface,
- (d) a source of a cover coating material,
- (e) means for conveying the substrate having the active coating layer to a position adjacent to the source of cover coating material, and
- (f) means for electrostatically applying the cover coating material onto the active coating layer, such that the cover coating material forms a cover coating layer which substantially completely covers the active coating layer.

52. An apparatus as claimed in claim 51, which includes means for electrostatically applying the active coating material.

53. An apparatus as claimed in claim 51 or claim 52, wherein the source of active coating material comprises a conveyor for conveying active coating material through a region in which the substrate is supported by the support means.

54. An apparatus as claimed in claim 53, further including means for supplying active coating material to the source, the supplying means comprising a reservoir of active coating material arranged adjacent to the conveyor, and means for transferring the active coating material from the reservoir to the conveyor.

55. An apparatus as claimed in claim 54, wherein the means for transferring the active coating material includes charging means for applying a charge to the conveyor.

56. An apparatus as claimed in claim 54 or claim 55, wherein the reservoir is arranged below the conveyor.

57. An apparatus as claimed in any one of claims 51 to 56, which includes means for applying a metered dose of active coating material on a surface of the substrate.

58. An apparatus as claimed in any one of claims 51 to 57, wherein the source comprises an ink jet head.

59. An apparatus as claimed in any one of claims 51 to 58, which includes means for directing droplets of liquid active coating material towards a surface of the substrate.

60. An apparatus as claimed in any of claims 51 to 59, wherein the apparatus is adapted for applying active coating material from the source onto only a part of the exposed surface of the substrate.

61. An apparatus as claimed in any of claims 51 to 60, wherein the means for applying the cover coating material includes means for directing cover coating material onto the surface of the substrate in the form of a jet of liquid droplets.

62. An apparatus as claimed in any of claims 51 to 61, wherein the apparatus is adapted for applying a cover coating material onto only a part of the exposed surface of the substrate.

63. An apparatus as claimed in any one of claims 51 to 62, which includes means for dividing the coated substrate before or after application of the cover coating material to form a plurality of solid dosage forms.

64. A pharmaceutical product comprising a substrate, a fused-film active coating layer on a surface of the substrate, the active coating layer comprising biologically active material, and a fused-film cover coating layer that has been applied electrostatically, on the active coating layer, substantially completely covering the active coating layer.

65. A pharmaceutical product as claimed in claim 64, wherein the active coating layer comprises:

- i) a continuous phase component,
- ii) the biologically active material,
- iii) a charge-modifying component, and
- iv) a flow aid.

66. A pharmaceutical product as claimed in claim 64 or claim 65, which is a solid dosage form as specified in any one of claims 31 to 33.

67. A pharmaceutical product as claimed in claim 64 or claim 65, wherein the total quantity of active coating material in the coated substrate is substantially equal to a dose of the active material.

68. A pharmaceutical product as claimed in claim 64 or claim 65, wherein the product is divisible into layered portions each including substantially one dose of biologically active material.

69. A pharmaceutical product as claimed in claim 65, wherein there is a plurality of regions of fused-film active coating material on a surface of the substrate, each region of active coating material containing substantially one dose of biologically active material.

70. A pharmaceutical product as claimed in any one of claims 64 to 69, which is in the form of a film or sheet.

71. A pharmaceutical product as claimed in any one of claims 64 to 70, wherein the coverage of the substrate is as specified in any one of claims 15 to 17.

72. A pharmaceutical product as claimed in any one of claims 64 to 71, wherein the cover coating layer is as specified in any one of claims 18 to 21.

73. A pharmaceutical product as claimed in any one of claims 64 to 72, which includes one or more further coating layers as specified in any one of claims 22 to 29.

74. A pharmaceutical product as claimed in any one of claims 64 to 67 or any one of claims 71 to 73, wherein the product is a tablet as specified in claim 35 or claim 36.

75. A pharmaceutical product as claimed in any one of claims 64 to 74, wherein the substrate is as specified in any one of claims 43 to 47.

Patentansprüche

1. Verfahren zur Beschichtung eines pharmazeutischen Substrats, wobei das Verfahren die Schritte umfaßt:

- (a) Auftragen eines Wirkschichtmaterials auf die Oberfläche des Substrats, um eine Wirkschicht zu bilden, wobei das Wirkschichtmaterial biologisch wirksames Material umfaßt, und
- (b) elektrostatisches Auftragen eines Deckschichtmaterials auf die Wirkschicht, um eine Deckschicht zu bilden, so daß die Wirkschicht im wesentlichen vollständig von der Deckschicht bedeckt wird.

2. Verfahren gemäß Anspruch 1, bei dem das Wirkschichtmaterial elektrostatisch aufgetragen wird.

3. Verfahren gemäß Anspruch 1 oder Anspruch 2, bei dem das Wirkschichtmaterial in Form eines Trockenpulvers aufgetragen wird.

4. Verfahren gemäß Anspruch 3, bei dem wenigstens 90 Gew.-% der Wirkschichtmaterialteilchen eine Teilchengröße im Bereich von 1 µm bis 45 µm besitzen.

5. Verfahren gemäß irgendeinem der Ansprüche 1 bis 4, bei dem das Wirkschichtmaterial in Form eines Strahls aus Beschichtungsmaterialteilchen aufgetragen wird.

6. Verfahren gemäß irgendeinem der Ansprüche 1 bis 5, bei dem das Wirkschichtmaterial in Form einer Flüssigkeit aufgetragen wird.

7. Verfahren gemäß Anspruch 6, bei dem das Wirkschichtmaterial in Form von einzelnen Flüssigkeitströpfchen aufgetragen wird, welche aus dem Vorrat direkt auf die Substratoberfläche geschleudert werden.

8. Verfahren gemäß Anspruch 6 oder Anspruch 7, bei dem eine vorherbestimmte Anzahl an Wirkschichtmaterialtröpfchen auf die Substratoberfläche aufgetragen wird.

9. Verfahren gemäß irgendeinem der Ansprüche 6 bis 8, bei dem das Wirkschichtmaterial in Form eines Flüssigkeitströpfchenstrahls auf die freiliegende Substratoberfläche aufgetragen wird.

10. Verfahren gemäß irgendeinem der Ansprüche 1 bis 9, bei dem ein Tintenstrahlkopf verwendet wird, um Wirkschichtmaterial auf das Substrat aufzutragen.

11. Verfahren gemäß irgendeinem der Ansprüche 1 bis 10, bei dem das Verfahren ferner den Schritt umfaßt, bei dem, nachdem die Wirkschicht aufgetragen worden ist, das Wirkschichtmaterial behandelt wird, um eine auf der Substratoberfläche haftende Wirkfilmschicht zu bilden.

12. Verfahren gemäß Anspruch 11, bei dem das Wirkschichtmaterial in Form eines Pulvers vorliegt und das Wirkschichtmaterial, nachdem die Wirkschicht aufgetragen worden ist, behandelt wird, um eine auf der Substratoberfläche haftende Schmelzfilmschicht zu bilden.

13. Verfahren gemäß irgendeinem der Ansprüche 1 bis 12, bei dem das Deckschichtmaterial in Form eines Pulvers vorliegt.
14. Verfahren gemäß Anspruch 13, bei dem das Deckschichtmaterial, nachdem die Deckschicht aufgetragen worden ist, behandelt wird, um eine auf der Substratoberfläche haftende Deck-Schmelzfilmschicht zu bilden.
15. Verfahren gemäß irgendeinem der Ansprüche 1 bis 14, bei dem das Wirkschichtmaterial nur auf einen Teil der Substratoberfläche aufgetragen wird.
16. Verfahren gemäß Anspruch 15, bei dem die Wirkschicht in Form eines Punktes vorliegt oder ein Muster, Bild, Symbol, einen Buchstaben oder eine Zahl bildet.
17. Verfahren gemäß Anspruch 15 oder Anspruch 16, bei dem das Deckschichtmaterial nur einen Teil der Substratoberfläche bedeckt.
18. Verfahren gemäß irgendeinem der Ansprüche 1 bis 17, bei dem die Deckschicht für eine gesteuerte Freisetzung des biologisch wirksamen Materials sorgt.
19. Verfahren gemäß irgendeinem der Ansprüche 1 bis 18, bei dem die Deckschicht biologisch wirksames Material enthält.
20. Verfahren gemäß Anspruch 19, bei dem das biologisch wirksame Material in der Deckschicht das gleiche ist wie das in der Wirkschicht.
21. Verfahren gemäß Anspruch 19, bei dem das biologisch wirksame Material in der Deckschicht sich von dem in der Wirkschicht unterscheidet.
22. Verfahren gemäß irgendeinem der Ansprüche 1 bis 21, bei dem das Verfahren ferner den Schritt des Auftragens eines zusätzlichen Beschichtungsmaterials auf eine Substratoberfläche umfaßt, um eine zusätzliche Schicht zu bilden.
23. Verfahren gemäß Anspruch 22, bei dem das Material für die zusätzliche Schicht biologisch wirksames Material umfaßt, wobei die zusätzliche Schicht eine zusätzliche Wirkschicht bildet.
24. Verfahren gemäß Anspruch 23, bei dem das Verfahren ferner den Schritt des Auftragens eines zusätzlichen Deckschichtmaterials auf die zusätzliche Wirkschicht umfaßt, um eine zusätzliche Deckschicht zu bilden, so daß die zusätzliche Wirkschicht im wesentlichen vollständig von der zusätzlichen Deckschicht bedeckt ist.
25. Verfahren gemäß Anspruch 24, bei dem das biologisch wirksame Material in der zusätzlichen Wirkschicht sich von dem in der ersten Wirkschicht unterscheidet.
26. Verfahren gemäß Anspruch 25, bei dem das biologisch wirksame Material in der zusätzlichen Wirkschicht das gleiche ist wie das in der ersten Wirkschicht und bei dem die Deckschichtmaterialien verschieden sind.
27. Verfahren gemäß irgendeinem der Ansprüche 24 bis 26, bei dem eines oder mehrere der Deckschichtmaterialien biologisch wirksames Material enthält/enthalten.
28. Verfahren gemäß irgendeinem der Ansprüche 1 bis 21, bei dem das Verfahren ferner die Schritte des Auftragens eines zusätzlichen Beschichtungsmaterials, das biologisch wirksames Material enthält, um eine zweite Wirkschicht zu bilden, und des Auftragens eines zusätzlichen Deckschichtmaterials auf die zweite Wirkschicht, um eine zusätzliche Deckschicht zu bilden, umfaßt, so daß die zweite Wirkschicht im wesentlichen vollständig von der zusätzlichen Deckschicht bedeckt ist.
29. Verfahren gemäß Anspruch 28, bei dem die Deckschicht, welche die erste Wirkschicht bedeckt, sich von der Deckschicht, welche die zweite Wirkschicht bedeckt, unterscheidet.
30. Verfahren gemäß irgendeinem der Ansprüche 1 bis 29, bei dem das Substrat in Form einer Folie oder eines flächigen Materials vorliegt.

31. Verfahren gemäß irgendeinem der Ansprüche 1 bis 30, bei dem das beschichtete pharmazeutische Substrat eine feste Dosisform ist.

32. Verfahren gemäß Anspruch 31, bei dem die feste Dosisform zur oralen Verabreichung hergerichtet ist.

33. Verfahren gemäß Anspruch 32, bei dem die feste Dosisform eine Tablette oder Kapsel ist.

34. Verfahren gemäß irgendeinem der Ansprüche 1 bis 30, bei dem die Gesamtmenge an biologisch wirksamem Material in dem beschichteten Substrat im wesentlichen einer Dosis des wirksamen Materials entspricht.

35. Verfahren gemäß irgendeinem der Ansprüche 24 bis 27, bei dem das pharmazeutische Substrat ein Tablettenkern ist und die erste Wirkschicht eine Seite bedeckt und die zweite Wirkschicht die gegenüberliegende Seite bedeckt.

36. Verfahren gemäß Anspruch 35, bei dem, um unterschiedliche Freisetzungsraten zu erzielen, die Deckschicht, welche die erste Wirkschicht bedeckt, sich von der Deckschicht, welche die zweite Wirkschicht bedeckt, unterscheidet.

37. Verfahren gemäß irgendeinem der Ansprüche 1 bis 30, bei dem mehrere Bereiche aus Wirkschichtmaterial auf die Substratoberfläche aufgetragen werden.

38. Verfahren gemäß irgendeinem der Ansprüche 1 bis 30 oder Anspruch 37, wobei das Verfahren den Schritt des Teilens des beschichteten Substrats umfaßt, um mehrere feste Dosisformen zu bilden.

39. Verfahren gemäß Anspruch 38, bei dem die Deckschicht aufgetragen wird, bevor das beschichtete Substrat geteilt wird.

40. Verfahren gemäß Anspruch 37, bei dem die Deckschicht aufgetragen wird, nachdem das beschichtete Substrat geteilt worden ist.

41. Verfahren gemäß irgendeinem der Ansprüche 1 bis 30, welches die Schritte umfaßt:

- (a) Auftragen mehrerer Bereiche aus Wirkschichtmaterial auf die Substratoberfläche, wobei das Wirkschichtmaterial biologisch wirksames Material umfaßt und die Menge an auf jeden Bereich aufgetragenem Wirkschichtmaterial derart ist, daß im wesentlichen eine Dosis biologisch wirksames Material enthalten ist, und
- (b) elektrostatisches Auftragen eines Deckschichtmaterials auf das Wirkschichtmaterial, so daß das Wirkschichtmaterial im wesentlichen vollständig von dem Deckschichtmaterial bedeckt wird, und Teilen des beschichteten Substrats vor oder nach dem Auftrag des Deckschichtmaterials, so daß jeder abgetrennte Teil im wesentlichen eine Dosis biologisch wirksames Material enthält.

42. Verfahren gemäß irgendeinem der Ansprüche 1 bis 30, bei dem das schichtförmige Produkt geteilt wird, um schichtförmige Teile zu bilden, wobei jeder schichtförmige Teil im wesentlichen eine Dosis des biologisch wirksamen Materials enthält.

43. Verfahren gemäß irgendeinem der Ansprüche 1 bis 42, bei dem das Substrat das gleiche biologisch wirksame Material enthält wie das, das auf das Substrat aufgetragen worden ist.

44. Verfahren gemäß irgendeinem der Ansprüche 1 bis 42, bei dem das Substrat biologisch wirksames Material enthält, welches sich von dem, das auf das Substrat aufgetragen worden ist, unterscheidet.

45. Verfahren gemäß Anspruch 44, bei dem das Substrat und die Wirkschicht unterschiedliche Freisetzungsraten besitzen.

46. Verfahren gemäß irgendeinem der Ansprüche 43 bis 45, bei dem das Substrat eine Tablette ist, die biologisch wirksames Material enthält und die vor dem Auftrag des Wirkschichtmaterials mit einer Schicht mit verzögerter Freisetzung beschichtet wurde.

47. Verfahren gemäß irgendeinem der Ansprüche 1 bis 42, bei dem das Substrat kein biologisch wirksames Material enthält.

48. Verfahren gemäß irgendeinem der Ansprüche 1 bis 47, bei dem das Substrat während der Beschichtung mit dem Wirkschichtmaterial und/oder dem Deckschichtmaterial auf einem Haltemittel festgehalten wird.
- 5 49. Verfahren gemäß Anspruch 48, wobei das Verfahren das Festhalten des Substrats neben der Quelle des Wirkschichtmaterials und/oder des Deckschichtmaterials umfaßt, derart, daß eine Oberfläche des Substrats bei einem elektrischen Potential gehalten wird, das sich derart von dem des Wirkschichtmaterials und/oder des Deckschichtmaterials unterscheidet, daß das Anlegen des elektrischen Potentials dazu führt, daß sich das Wirkschichtmaterial und/oder das Deckschichtmaterial von der Quelle des Wirkschichtmaterials und/oder des Deckschichtmaterials zum Substrat hin bewegt/bewegen, wobei eine Oberfläche des Substrats mit dem Wirkschichtmaterial und/oder dem Deckschichtmaterial beschichtet wird.
- 10 50. Verfahren gemäß Anspruch 48 oder Anspruch 49, bei dem das Substrat von oben her gehalten wird und das Pulver sich von der Quelle nach oben auf eine untere Oberfläche des Substrats zubewegt.
- 15 51. Vorrichtung zur Beschichtung eines pharmazeutischen Substrats, wobei die Vorrichtung umfaßt:
- (a) eine Wirkschichtmaterialquelle, wobei das Wirkschichtmaterial biologisch wirksames Material umfaßt,
 - (b) ein Haltemittel zum Festhalten eines Substrats neben der Wirkschichtmaterialquelle,
 - (c) ein Mittel zum Auftragen des Wirkschichtmaterials auf eine Oberfläche des Substrats, so daß das Wirkschichtmaterial eine Wirkschicht auf der Oberfläche bildet,
 - (d) eine Deckschichtmaterialquelle,
 - (e) ein Mittel zur Beförderung des Substrats, auf dem sich die Wirkschicht befindet, in eine Position neben der Deckschichtmaterialquelle,
 - (F) ein Mittel zum elektrostatischen Auftragen des Deckschichtmaterials auf die Wirkschicht, so daß das Deckschichtmaterial eine Deckschicht bildet, welche die Wirkschicht im wesentlichen vollständig bedeckt.
- 20 52. Vorrichtung gemäß Anspruch 51, die ein Mittel zum elektrostatischen Auftragen des Wirkschichtmaterials umfaßt.
- 30 53. Vorrichtung gemäß Anspruch 51 oder Anspruch 52, bei der die Wirkschichtmaterialquelle eine Fördereinrichtung zur Beförderung von Wirkschichtmaterial durch einen Bereich, in dem das Substrat durch das Haltemittel festgehalten wird, umfaßt.
- 35 54. Vorrichtung gemäß Anspruch 53, die ferner ein Mittel zur Versorgung der Quelle mit Wirkschichtmaterial umfaßt, wobei das Versorgungsmittel einen Wirkschichtmaterial-Vorratsbehälter, der sich neben der Fördereinrichtung befindet, und ein Mittel zur Beförderung des Wirkschichtmaterials von dem Vorratsbehälter zur Fördereinrichtung umfaßt.
- 40 55. Vorrichtung gemäß Anspruch 54, bei der das Mittel zum Transport des Wirkschichtmaterials ein Auflademittel zum Anlegen einer Ladung an die Fördereinrichtung umfaßt.
- 45 56. Vorrichtung gemäß Anspruch 54 oder Anspruch 55, bei der sich der Vorratsbehälter unter der Fördereinrichtung befindet.
- 50 57. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 56, die ein Mittel zum Auftragen einer abgemessenen Wirkschichtmaterialdosis auf eine Oberfläche des Substrats umfaßt.
58. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 57, bei der die Quelle einen Tintenstrahlkopf umfaßt.
59. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 58, die ein Mittel enthält, um Tröpfchen aus flüssigem Wirkschichtmaterial auf eine Oberfläche des Substrats zu leiten.
60. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 59, wobei die Vorrichtung hergerichtet ist, um Wirkschichtmaterial aus der Quelle nur auf einen Teil der freiliegenden Oberfläche des Substrats aufzutragen.
- 55 61. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 60, bei der das Mittel zum Auftragen des Deckschichtmaterials ein Mittel enthält, welches das Deckschichtmaterial in Form eines Strahls flüssiger Tröpfchen auf die Oberfläche des Substrats leitet.

62. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 61, wobei die Vorrichtung hergerichtet ist, um ein Deckschichtmaterial nur auf einen Teil der freiliegenden Oberfläche des Substrats aufzutragen.

63. Vorrichtung gemäß irgendeinem der Ansprüche 51 bis 62, die ein Mittel zum Teilen des beschichteten Substrats vor oder nach dem Auftragen des Deckschichtmaterials umfaßt, um mehrere feste Dosisformen zu bilden.

64. Pharmazeutisches Produkt, umfassend ein Substrat, eine Schmelzfilm-Wirkschicht auf einer Oberfläche des Substrats, wobei die Wirkschicht biologisch wirksames Material umfaßt, und eine Schmelzfilm-Deckschicht, welche elektrostatisch auf die Wirkschicht aufgetragen worden ist und die Wirkschicht im wesentlichen vollständig bedeckt.

65. Pharmazeutisches Produkt gemäß Anspruch 64, bei dem die Wirkschicht umfaßt:

- i) eine Komponente, die eine kontinuierliche Phase ist,
- ii) das biologisch wirksame Material,
- iii) eine ladungsmodifizierende Komponente und
- iv) ein Fließhilfsmittel.

66. Pharmazeutisches Produkt gemäß Anspruch 64 oder Anspruch 65, das eine feste Dosisform ist, wie sie in irgendeinem der Ansprüche 31 bis 33 angegeben ist.

67. Pharmazeutisches Produkt gemäß Anspruch 64 oder Anspruch 65, wobei die Gesamtmenge des Wirkschichtmaterials in dem beschichteten Substrat im wesentlichen einer Dosis des wirksamen Materials entspricht.

68. Pharmazeutisches Produkt gemäß Anspruch 64 oder Anspruch 65, wobei das Produkt in schichtförmige Teile teilbar ist, die jeweils im wesentlichen eine Dosis biologisch wirksamen Materials enthalten.

69. Pharmazeutisches Produkt gemäß Anspruch 65, bei dem mehrere Bereiche aus Schmelzfilm-Wirkschichtmaterial auf einer Substratoberfläche vorliegen, wobei jeder Wirkschichtmaterialbereich im wesentlichen eine Dosis biologisch wirksamen Materials enthält.

70. Pharmazeutisches Produkt gemäß irgendeinem der Ansprüche 64 bis 69, das in Form einer Folie oder eines flächigen Materials vorliegt.

71. Pharmazeutisches Produkt gemäß irgendeinem der Ansprüche 64 bis 70, bei dem die Bedeckung des Substrats derart ist, wie es in irgendeinem der Ansprüche 15 bis 17 angegeben ist.

72. Pharmazeutisches Produkt gemäß irgendeinem der Ansprüche 64 bis 71, bei dem die Deckschicht derart ist, wie es in irgendeinem der Ansprüche 18 bis 21 angegeben ist.

73. Pharmazeutisches Produkt gemäß irgendeinem der Ansprüche 64 bis 72, das eine oder mehrere zusätzliche Beschichtungen umfaßt, wie es in irgendeinem der Ansprüche 22 bis 29 angegeben ist.

74. Pharmazeutisches Produkt gemäß irgendeinem der Ansprüche 64 bis 67 oder irgendeinem der Ansprüche 71 bis 73, wobei das Produkt eine wie in Anspruch 35 oder Anspruch 36 angegebene Tablette ist.

75. Pharmazeutisches Produkt gemäß irgendeinem der Ansprüche 64 bis 74, wobei das Substrat derart ist, wie es in irgendeinem der Ansprüche 43 bis 47 angegeben ist.

Revendications

1. Procédé pour revêtir un substrat pharmaceutique, le procédé comprenant les étapes de :

- (a) application d'une matière de revêtement active sur une surface du substrat pour former une couche de revêtement active, la matière de revêtement active comprenant une matière biologiquement active, et
- (b) application par voie électrostatique d'une matière de revêtement de couverture sur la couche de revêtement active pour former une couche de revêtement de couverture telle que la couche de revêtement active est substantiellement complètement recouverte par la couche de revêtement de couverture.

2. Procédé selon la revendication 1, dans lequel la matière de revêtement active est appliquée par voie électrostatique.
3. Procédé selon la revendication 1 ou la revendication 2, dans lequel la matière de revêtement active est appliquée sous la forme d'une poudre sèche.
4. Procédé selon la revendication 3, dans lequel au moins 90% en poids des particules de la matière de revêtement active ont une taille de particule comprise dans la gamme de 1 μm à 45 μm .
5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la matière de revêtement active est appliquée sous la forme d'un jet de particules de matière de revêtement.
6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la matière de revêtement active est appliquée sous la forme d'un liquide.
7. Procédé selon la revendication 6, dans lequel la matière de revêtement active est appliquée sous la forme de gouttelettes liquides individuelles qui sont propulsées depuis l'alimentation directement vers une surface du substrat.
8. Procédé selon la revendication 6 ou la revendication 7, dans lequel un nombre prédéterminé de gouttelettes de matière de revêtement active est appliqué à la surface du substrat.
9. Procédé selon l'une quelconque des revendications 6 à 8, dans lequel la matière de revêtement active est appliquée sous la forme d'un jet de gouttelettes liquides dirigé vers une surface exposée du substrat.
10. Procédé selon l'une quelconque des revendications 1 à 9, dans lequel une tête à jet d'encre est utilisée pour appliquer la matière de revêtement active sur le substrat.
11. Procédé selon l'une quelconque des revendications 1 à 10, dans lequel le procédé comprend de plus l'étape selon laquelle après application de la couche de revêtement active, la matière de revêtement active est traitée pour former un revêtement pelliculaire actif fixé à la surface du substrat.
12. Procédé selon la revendication 11, dans lequel la matière de revêtement active est sous la forme d'une poudre et après application de la couche de revêtement active, la matière de revêtement active est traitée pour former un revêtement pelliculaire fondu fixé à la surface du substrat.
13. Procédé selon l'une quelconque des revendications 1 à 12, dans lequel la matière de revêtement de couverture est sous la forme d'une poudre.
14. Procédé selon la revendication 13, dans lequel après application de la couche de revêtement de couverture, la matière de revêtement de couverture est traitée pour former un revêtement pelliculaire de couverture fondu fixé à la surface du substrat.
15. Procédé selon l'une quelconque des revendications 1 à 14, dans lequel la matière de revêtement active est appliquée seulement sur une partie de la surface du substrat.
16. Procédé selon la revendication 15, dans lequel la couche de revêtement active est sous la forme d'une tache ou forme un motif, un dessin, un symbole, une lettre ou un chiffre.
17. Procédé selon la revendication 15 ou la revendication 16, dans lequel la matière de revêtement de couverture couvre seulement une partie de la surface du substrat.
18. Procédé selon l'une quelconque des revendications 1 à 17, dans lequel la couche de revêtement de couverture fournit une libération contrôlée de la matière biologiquement active.
19. Procédé selon l'une quelconque des revendications 1 à 18, dans lequel le revêtement de couverture comprend une matière biologiquement active.

20. Procédé selon la revendication 19, dans lequel la matière biologiquement active dans le revêtement de couverture est la même que celle qui est dans le revêtement actif.

21. Procédé selon la revendication 19, dans lequel la matière biologiquement active dans le revêtement de couverture est différente de celle qui est dans le revêtement actif.

22. Procédé selon l'une quelconque des revendications 1 à 21, dans lequel le procédé comprend de plus l'étape d'application d'une matière de revêtement supplémentaire sur une surface du substrat pour former une couche de revêtement supplémentaire.

23. Procédé selon la revendication 22, dans lequel la matière de revêtement supplémentaire comprend une matière biologiquement active, la couche de revêtement supplémentaire formant une couche de revêtement active supplémentaire.

24. Procédé selon la revendication 23, dans lequel le procédé comprend de plus l'étape d'application d'une matière de revêtement de couverture supplémentaire sur la couche de revêtement active supplémentaire pour former une couche de revêtement de couverture supplémentaire de telle sorte que la couche de revêtement active supplémentaire est substantiellement complètement recouverte par la couche de revêtement de couverture supplémentaire.

25. Procédé selon la revendication 24, dans lequel la matière biologiquement active dans la couche de revêtement active supplémentaire est différente de celle qui est présente dans la première couche de revêtement active.

26. Procédé selon la revendication 25, dans lequel la matière biologiquement active dans la couche de revêtement active supplémentaire est la même que celle qui est présente dans la première couche de revêtement active, et les matières de revêtement de couverture sont différentes.

27. Procédé selon l'une quelconque des revendications 24 à 26, dans lequel une ou plusieurs des matières de revêtement de couverture contiennent une matière biologiquement active.

28. Procédé selon l'une quelconque des revendications 1 à 21, dans lequel le procédé comprend de plus les étapes d'application d'une matière de revêtement supplémentaire qui comprend une matière biologiquement active pour former une seconde couche de revêtement active, et d'application d'une matière de revêtement de couverture supplémentaire sur la seconde couche de revêtement active pour former une couche de revêtement de couverture supplémentaire de telle sorte que la seconde couche de revêtement active est substantiellement complètement recouverte par la couche de revêtement de couverture supplémentaire.

29. Procédé selon la revendication 28, dans lequel la couche de revêtement de couverture recouvrant la première couche de revêtement active est différente de la couche de revêtement de couverture recouvrant la seconde couche de revêtement active.

30. Procédé selon l'une quelconque des revendications 1 à 29, dans lequel le substrat est sous la forme d'un film ou d'une feuille.

31. Procédé selon l'une quelconque des revendications 1 à 30, dans lequel le substrat pharmaceutique revêtu présente une forme posologique solide.

32. Procédé selon la revendication 31, dans lequel la forme posologique solide est destinée à une administration orale.

33. Procédé selon la revendication 32, dans lequel la forme d'administration solide est un comprimé ou une gélule.

34. Procédé selon l'une quelconque des revendications 1 à 30, dans lequel la quantité totale de matière biologiquement active dans le substrat revêtu est substantiellement égale à une dose de la matière active.

35. Procédé selon l'une quelconque des revendications 24 à 27, dans lequel le substrat pharmaceutique est un noyau de comprimé et la première couche de revêtement active recouvre l'une des faces et la seconde couche de revêtement active recouvre la face opposée.

36. Procédé selon la revendication 35, dans lequel, pour fournir des vitesses de libération différentes, la couche de revêtement de couverture recouvrant la première couche de revêtement active est différente de la couche de revêtement de couverture recouvrant la seconde couche de revêtement active.

5 37. Procédé selon l'une quelconque des revendications 1 à 30, dans lequel une pluralité de régions de matière de revêtement active est appliquée sur la surface du substrat.

38. Procédé selon l'une quelconque des revendications 1 à 30 ou la revendication 37, lequel procédé comprend l'étape de division du substrat revêtu pour former une pluralité de formes posologiques solides.

10 39. Procédé selon la revendication 38, dans lequel le revêtement de 1 couverture est appliqué avant la division du substrat revêtu.

40. Procédé selon la revendication 37, dans lequel le revêtement de couverture est appliqué après division du substrat revêtu.

15 41. Procédé selon l'une quelconque des revendications 1 à 30, qui comprend les étapes de :

20 (a) application d'une pluralité de régions de matière de revêtement active sur une surface du substrat, la matière de revêtement active comprenant une matière biologiquement active, la quantité de matière de revêtement active appliquée sur chaque région étant telle qu'elle contient substantiellement une dose de matière biologiquement active, et

(b) application par voie électrostatique d'une matière de revêtement de couverture sur la matière de revêtement active de telle sorte que la matière de revêtement active est substantiellement complètement recouverte par la matière de revêtement de couverture,

et division du substrat revêtu avant ou après l'application de la matière de revêtement de couverture de telle sorte que chaque partie divisée contient substantiellement une dose de matière biologiquement active.

30 42. Procédé selon l'une quelconque des revendications 1 à 30, dans lequel le produit en couches est divisé pour former des parties en couches, chaque partie en couches comprenant substantiellement une dose de la matière biologiquement active.

35 43. Procédé selon l'une quelconque des revendications 1 à 42, dans lequel le substrat contient la même matière biologiquement active que celle qui est appliquée sur le substrat.

44. Procédé selon l'une quelconque des revendications 1 à 42, dans lequel le substrat contient une matière biologiquement active différente de celle qui est appliquée sur le substrat.

40 45. Procédé selon la revendication 44, dans lequel le substrat et la couche de revêtement active ont des vitesses de libération différentes.

45 46. Procédé selon l'une quelconque des revendications 43 à 45, dans lequel le substrat est un comprimé contenant une matière biologiquement active revêtu d'un revêtement à libération retardée avant application de la matière de revêtement active.

47. Procédé selon l'une quelconque des revendications 1 à 42, dans lequel le substrat ne contient aucune matière biologiquement active.

50 48. Procédé selon l'une quelconque des revendications 1 à 47, dans lequel le substrat est supporté sur un moyen de support pendant le revêtement avec la matière de revêtement active et/ou la matière de revêtement de couverture.

55 49. Procédé selon la revendication 48, dans lequel le procédé comprend le support du substrat adjacent à la source de la matière de revêtement active et/ou de la matière de revêtement de couverture avec une surface du substrat maintenue à un potentiel électrique différent de celui de la matière de revêtement active et/ou de la matière de revêtement de couverture respectivement, tel que l'application du potentiel électrique provoque le déplacement de la matière de revêtement active et/ou de la matière de revêtement de couverture depuis la source de la matière de revêtement active et/ou de la matière de revêtement de couverture en direction du substrat, une surface du

substrat devenant revêtue de la matière de revêtement active et/ou de la matière de revêtement de couverture.

50. Procédé selon la revendication 48 ou la revendication 49, dans lequel le substrat est maintenu par le dessus et la poudre se déplace de la source vers le haut en direction d'une surface inférieure du substrat.

51. Appareil pour le revêtement d'un substrat pharmaceutique, l'appareil comprenant :

- (a) une source de matière de revêtement active, la matière de revêtement active comprenant une matière biologiquement active,
- (b) un moyen de support pour supporter un substrat adjacent à la source de la matière de revêtement active,
- (c) un moyen pour appliquer la matière de revêtement active sur une surface du substrat de telle sorte que la matière de revêtement active forme une couche de revêtement active sur la surface;
- (d) une source d'une matière de revêtement de couverture,
- (e) un moyen pour acheminer le substrat portant la couche de revêtement active vers une position adjacente à la source de matière de revêtement de couverture, et
- (f) un moyen pour appliquer par voie électrostatique la matière de revêtement de couverture sur la couche de revêtement active, de telle sorte que la matière de revêtement de couverture forme une couche de revêtement de couverture qui recouvre substantiellement complètement la couche de revêtement active.

52. Appareil selon la revendication 51, qui comprend un moyen pour appliquer par voie électrostatique la matière de revêtement active.

53. Appareil selon la revendication 51 ou la revendication 52, dans lequel la source de matière de revêtement active comprend un transporteur pour acheminer la matière de revêtement active à travers une région dans laquelle le substrat est supporté par le moyen de support.

54. Appareil selon la revendication 53, comprenant de plus un moyen pour alimenter la source en matière de revêtement active, le moyen d'alimentation comprenant un réservoir de matière de revêtement active disposé à côté du transporteur, et un moyen pour transférer la matière de revêtement active du réservoir vers le transporteur.

55. Appareil selon la revendication 54, dans lequel le moyen pour transférer la matière de revêtement active comprend un moyen de charge pour appliquer une charge au transporteur.

56. Appareil selon la revendication 54 ou la revendication 55, dans lequel le réservoir est disposé en dessous du transporteur.

57. Appareil selon l'une quelconque des revendications 51 à 56, qui comprend un moyen pour appliquer une dose mesurée de matière de revêtement active sur une surface du substrat.

58. Appareil selon l'une quelconque des revendications 51 à 57, dans lequel la source comprend une tête à jet d'encre.

59. Appareil selon l'une quelconque des revendications 51 à 58, qui comprend un moyen pour diriger des gouttelettes de matière de revêtement active liquide en direction d'une surface du substrat.

60. Appareil selon l'une quelconque des revendications 51 à 59, dans lequel l'appareil est adapté pour appliquer une matière de revêtement active à partir de la source sur seulement une partie de la surface exposée du substrat.

61. Appareil selon l'une quelconque des revendications 51 à 60, dans lequel le moyen pour appliquer la matière de revêtement de couverture comprend un moyen pour diriger la matière de revêtement de couverture sur la surface du substrat sous la forme d'un jet de gouttelettes liquides.

62. Appareil selon l'une quelconque des revendications 51 à 61, dans lequel l'appareil est adapté pour appliquer une matière de revêtement de couverture sur seulement une partie de la surface exposée du substrat.

63. Appareil selon l'une quelconque des revendications 51 à 62, qui comprend un moyen pour diviser le substrat revêtu avant ou après application de la matière de revêtement de couverture pour former une pluralité de formes posologiques solides.

64. Produit pharmaceutique comprenant un substrat, une couche pelliculaire fondue de revêtement active sur une surface du substrat, la couche de revêtement active comprenant une matière biologiquement active, et une couche pelliculaire fondue de revêtement de couverture qui a été appliquée par voie électrostatique sur la couche de revêtement active, recouvrant substantiellement complètement la couche de revêtement active.

65. Produit pharmaceutique selon la revendication 64, dans lequel la couche de revêtement active comprend :

- (i) un composant en phase continue,
- (ii) la matière biologiquement active,
- (iii) un composant modifiant la charge, et
- (iv) un agent facilitant l'écoulement.

66. Produit pharmaceutique selon la revendication 64 ou la revendication 65, qui est une forme posologique solide telle que spécifiée dans l'une quelconque des revendications 31 à 33.

67. Produit pharmaceutique selon la revendication 64 ou la revendication 65, dans lequel la quantité totale de la matière de revêtement active dans le substrat revêtu est substantiellement égale à une dose de la matière active.

68. Produit pharmaceutique selon la revendication 64 ou la revendication 65, dans lequel le produit peut être divisé en couches comprenant chacune substantiellement une dose de matière biologiquement active.

69. Produit pharmaceutique selon la revendication 65, dans lequel il existe une pluralité de régions de matière de revêtement pelliculaire fondu active sur une surface du substrat, chaque région de matière de revêtement active contenant substantiellement une dose de matière biologiquement active.

70. Produit pharmaceutique selon l'une quelconque des revendications 64 à 69, qui est sous la forme d'un film ou d'une feuille.

71. Produit pharmaceutique selon l'une quelconque des revendications 64 à 70, dans lequel le recouvrement du substrat est tel que spécifié dans l'une quelconque des revendications 15 à 17.

72. Produit pharmaceutique selon l'une quelconque des revendications 64 à 71, dans lequel la couche de revêtement de couverture est telle que spécifiée dans l'une quelconque des revendications 18 à 21.

73. Produit pharmaceutique selon l'une quelconque des revendications 64 à 72, qui comprend une ou plusieurs couches de revêtement supplémentaires telles que spécifiées dans l'une quelconque des revendications 22 à 29.

74. Produit pharmaceutique selon l'une quelconque des revendications 64 à 67 ou l'une quelconque des revendications 71 à 73, dans lequel le produit est un comprimé tel que spécifié dans la revendication 35 ou la revendication 36.

75. Produit pharmaceutique selon l'une quelconque des revendications 64 à 74, dans lequel le substrat est tel que spécifié dans l'une quelconque des revendications 43 à 47.





